Correlation between gut microbiome and cognitive impairment in patients undergoing peritoneal dialysisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiome composition between 28 peritoneal dialysis (PD) patients and 29 non-dialysis end-stage renal disease patients, and between PD patients with and without cognitive impairment.
How was it studied?
Fecal samples underwent 16S rRNA sequencing. Cognitive status was assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), and patients were split into subgroups accordingly.
What did they find?
Prevotellaceae showed the largest structural difference, and Lactobacillus the largest abundance difference, between PD patients with cognitive impairment and those with normal cognition. Altered microbiota correlated with cognitive scores and serum markers, and predictive models built on Lactobacillaceae, Actinomycetaceae, and Prevotellaceae abundance distinguished the two groups, with Lactobacillus genus abundance reaching an AUC of 0.848.
Why it matters
Gut microbiome profiling could serve as an early, noninvasive tool to flag cognitive impairment risk in peritoneal dialysis patients.